News

Category — GS Paper 2 - Health ///Published — 2026-05-14 ///Exam — UPSC CSE Prelims ///Tags — Health, Issues Related to Women, Medical Science ///Category — GS Paper 2 - Health ///Published — 2026-05-14 ///Exam — UPSC CSE Prelims ///Tags — Health, Issues Related to Women, Medical Science ///

News · GS Paper 2 - Health

PCOS Renamed to PMOS: Understanding the Global Health Shift

PCOS has been officially renamed as Polyendocrine Metabolic Ovarian Syndrome (PMOS) effective May 2026, after a 14-year global effort. The renaming reflects the condition's true nature as a complex metabolic and hormonal disorder rather than merely an ovarian disease. This change is particularly significant for India, where 16-18% of women are affected, linked to the 'thrifty genotype' hypothesis increasing susceptibility to obesity and Type 2 diabetes.

2026-05-14

Published

—

Source

Quiz Questions

Article

Key Facts About the Renaming

New Name: Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Effective Date: May 2026
Duration of Effort: 14 years of global advocacy

Reasons for the Change to PMOS

Scientific Accuracy

The term "cysts" was considered misleading
The condition does not involve abnormal ovarian cysts
Instead, affected individuals have arrested follicular development that appears cyst-like on ultrasound

Multi-systemic Nature

Reflects the disorder's broader endocrine, metabolic, and ovarian dysfunction
Includes insulin resistance, hormonal imbalance, and reproductive abnormalities
Moves away from portraying it solely as a gynaecological disorder

Global Prevalence

Global: Affects 1 in 8 women
Undiagnosed: 70% of affected individuals remain undiagnosed
Aim: Reduce delayed diagnosis and ensure holistic treatment

Significance for India

Prevalence: 16-18% of women in India affected
Critical Factor: Inclusion of "metabolic" in the name is crucial for Indian population
Thrifty Genotype Hypothesis: Genetic predisposition to store energy efficiently, increasing risk of obesity and Type 2 diabetes

Clinical Characterization

Primary Identification: Chronic anovulation
Symptoms:
Irregular periods
Hirsutism (excessive hair growth)
Weight gain
High androgen levels

Risk Factors

Non-modifiable: Genetics, neuroendocrine disruptions
Modifiable: Sedentary lifestyle, poor diet, obesity

Treatment Approaches

Synthetic Drugs: Metformin and Oral Contraceptive Pills (OCPs) are standard
Emerging Research: Significant shift toward traditional and herbal medicines due to side effects of synthetic drugs